Core Laboratories N.V. (CLB) Tops Q2 EPS by 1c, Posts Strong Q3 and FY11 Guidance
Tweet
Share
E-mailGet Alerts CLB Hot Sheet
Price: $11.77 +0.68%
EPS Growth %: +36.4%
Financial Fact:
Income Tax Expense (Benefit): 2.08M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +36.4%
Financial Fact:
Income Tax Expense (Benefit): 2.08M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Core Laboratories N.V. (NYSE: CLB) reported Q2 EPS of $0.90, $0.01 better than the analyst estimate of $0.89. Revenue for the quarter came in at $225.79 million versus the consensus estimate of $219.56 million.
Core Laboratories N.V. sees Q3 2011 EPS of $0.98-$1.00, versus the consensus of $0.98. Core Laboratories N.V. sees Q3 2011 revenue of $230-$245 million, versus the consensus of $234.49 million.
Core Laboratories N.V. sees FY2011 EPS of $3.55-$3.60, versus the consensus of $3.69. Core Laboratories N.V. sees FY2011 revenue of $910-$930 million, versus the consensus of $906.93 million.
Core Laboratories N.V. sees Q3 2011 EPS of $0.98-$1.00, versus the consensus of $0.98. Core Laboratories N.V. sees Q3 2011 revenue of $230-$245 million, versus the consensus of $234.49 million.
Core Laboratories N.V. sees FY2011 EPS of $3.55-$3.60, versus the consensus of $3.69. Core Laboratories N.V. sees FY2011 revenue of $910-$930 million, versus the consensus of $906.93 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
- CarMax beats estimates as new strategy drives early results
- Jabil beats consensus estimates but shares dip
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
